Testing the Value of Novel Strategy and Its Cost Efficacy in Order to Improve the Poor Outcomes in Cardiogenic Shock (EUROSHOCK)
Cardiogenic Shock
About this trial
This is an interventional treatment trial for Cardiogenic Shock focused on measuring Cardiogenic Shock, Acute Myocardial Infarction, Acute Coronary Syndrome
Eligibility Criteria
Inclusion Criteria:
- Willing to provide informed consent/assent.
- Presentation CGS within 24 hours of onset of Acute Coronary Syndrome (ACS) symptoms.
- CGS can only be secondary to ACS (Type 1 MI STEMI or N-STEMI) or secondary to ACS following previous recent PCI (acute/sub-acute stent thrombosis ARC)
- PCI has been attempted.
Persistence of CGS 30 minutes after successful or unsuccessful revascularisation of culprit coronary artery to allow for echocardiography and clinical assessment.
CGS will be defined by the following 2 criteria:
• Systolic blood pressure <90 mmHg for at least 30 minutes, or a requirement for a continuous infusion of vasopressor or inotropic therapy to maintain systolic blood pressure > 90 mmHg.
Clinical signs of pulmonary congestion, plus signs of impaired organ perfusion with at least one of the following manifestations:
- altered mental status.
- cold and clammy skin and limbs.
- oliguria with a urine output of less than 30 ml per hour.
- elevated arterial lactate level of >2.0 mmol per litre.
- Provision of informed assent followed by patient consent; [or relative or physician consent if the patient is unable to consent].
Exclusion Criteria:
- Unwilling to provide informed assent/consent.
- Echocardiographic evidence) of mechanical cause for CGS: eg ventricular septal defect, LV-free wall rupture, ischaemic mitral regurgitation (recorded within 30 mins of end of PCI procedure).
- Age <18 and>90 years.
- Deemed appropriately frail (≥ 5 Canadian frailty score)
- Shock from another cause (sepsis, haemorrhagic/hypovolaemic shock, anaphylaxis, myocarditis etc.).
- Significant systemic illness
- Known dementia of any severity.
- Comorbidity with life expectancy <12 months.
- Severe peripheral vascular disease (precluding access making ECMO contra- indicated).
- Severe allergy or intolerance to pharmacological or antithrombotic anti-platelet agents.
Out-of-hospital cardiac arrest (OHCA) under any of the following circumstances:-
- without return of spontaneous circulation (ongoing resuscitation effort).
- without pH or >7 without bystander CPR within 10 minutes of collapse.
- Involved in another randomised research trial within the last 12 months.
- Arterial lactate level of <2.0 mmol per litre.
Sites / Locations
- Medical University of Vienna
- Algemeen Stedelijk Ziekenhuis Aalst
- Onze Lieve Vrouw Hospital Aalst
- University Hospital Antwerpen
- ZNA Middelheim
- Imelda Hospital Bonheiden
- AZ Monica
- AZ Gent
- Jessa Ziekenhuis Hasselt
- Katholieke Universiteit LeuvenRecruiting
- AZ Turnhout
- Universitäts-Herzzentrum Freiburg-Bad Krozingen
- Segeberger Kliniken GmbH
- Herz-Zentrum Bodensee
- Klinikum Rechts Der Isar
- Klinikum Campus InnenstadtRecruiting
- Deutsches Herzzentrum MünchenRecruiting
- Barmherzige Brüder gemeinnützige Krankenhaus GmbH
- Klinik Augustinum
- Ludwig-Maximilians-Universität MünchenRecruiting
- Uniklinikum Tübingen
- Azienda Ospedalierea Papa Giovanni XXIII
- University Hospital of Bologna Policlinico S. Orsola - Malpighi
- Azienda Universitaria Ospedaliera Careggi, Firenze
- Università degli Studi di Padova
- Ospedale San Giovanni Bosco di Torino
- Paula Stradina Liniska Universitates Slimnica ASRecruiting
- The Nordland Hospital
- The Finnmark Hospital
- The Helgeland Hospital
- Universitetet i TromsoeRecruiting
- Hospital Germans Trias I PujolRecruiting
- Hospital Vall d'HebronRecruiting
- Consorci Institut D'Investicacions Biomediques August Pi i Sunyer / Hospital Clinic de BarcelonaRecruiting
- Hospital de Sant Pau
- Hospital de BellvitgeRecruiting
- University Hospital Leicester
- Hairmyres Hospital
- University of LeicesterRecruiting
- Newcastle Freeman Hospital
- University of Glasgow
- Papworth Hospital
- Golden Jubilee National Hospital
- St Barts and the London Hospital
- Kings College HospitalRecruiting
- Harefield and Brompton LondonRecruiting
- Guys and St Thomas NHS Foundation Trust
Arms of the Study
Arm 1
Arm 2
Active Comparator
Experimental
Immediate PCI with medical therapy
Immediate PCI with early VA-ECMO
Group 1 will receive immediate revascularisation with Percutaneous Coronary Intervention (PCI) to the culpirit lesion only) + standard care (pharmacological support titrated to attain SBP >90mmHg). No mechanical support device allowed.
Group 2 will receive immediate PCI plus standard pharmacological support with early peripheral veno-arterial ECMO.